23andMe Holding Co. (MEHCQ)
OTCMKTS
· Delayed Price · Currency is USD
3.965
+0.115 (2.99%)
Jun 4, 2025, 4:00 PM EDT
23andMe Holding Co. Revenue
23andMe Holding Co. had revenue of $60.26M in the quarter ending December 31, 2024, with 34.67% growth. This brings the company's revenue in the last twelve months to $208.78M, down -15.81% year-over-year. In the fiscal year ending March 31, 2024, 23andMe Holding Co. had annual revenue of $219.64M, down -26.66%.
Revenue (ttm)
208.78M
Revenue Growth
-15.81%
P/S Ratio
0.49
Revenue / Employee
365.63K
Employees
582
Market Cap
103.28M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |
| American Oncology Network | 1.76B |
23andMe Holding Co. News
- 10 hours ago - 23andMe's Former CEO Pushes Purchase Price Nearly $50 Million Higher - WSJ
- 12 hours ago - 23andMe seeks new bids after $305 million offer from its co-founder - Reuters
- 2 days ago - 23andMe customers notified of bankruptcy - TechCrunch
- 3 days ago - 23andMe founder aims to restart auction with major corporate backing - Reuters
- 8 days ago - 23andMe to delist from Nasdaq, deregister with SEC - CNBC
- 8 days ago - 23andMe Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC - GlobeNewsWire
- 14 days ago - What Regeneron's Purchase Of 23andMe Means For Your Genetic Privacy - Forbes
- 15 days ago - Regeneron's 23andMe Steal: Smart Genetics Play That Won't Cure Near-Term Growth Pains - Seeking Alpha